Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today.

"2012 was a transformational year for Cempra," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra. "We raised sufficient capital through our IPO and a subsequent private placement to advance our two differentiated antibiotics in clinical development.  Solithromycin is now in the first of two planned Phase 3 clinical trials in community-acquired bacterial pneumonia or CABP and Taksta (CEM-102) is undergoing a Phase 2 trial in patients with prosthetic joint infections or PJIs.  2013 will also be an important year as we expect to hold an end-of-Phase 2 meeting with the FDA during the first half of 2013 for solithromycin in CABP as the key step in preparing for the IV-to-oral second Phase 3 trial, which we expect to start in the second half of 2013 subject to available resources.  We also anticipate presenting some top-line results for the TAKSTA™ Phase 2 trial in PJIs in the fourth quarter of 2013."

Financial ResultsQuarter ended December 31, 2012 compared to quarter ended December 31, 2011

For the quarter ended December 31, 2012, Cempra reported a net loss of $6.6 million, or $0.26 per share, compared to a net loss of $3.8 million, or $7.13 per share, for the same period in 2011. 

Research and development expense in the quarter ended December 31, 2012, was $4.4 million, a 20
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Slone Partners , a national ... and Laboratory Testing industries, reported a 120% increase in ... level and above from July 2013 to July 2014. ... of rapid breakthroughs in diagnostics, reimbursement has failed to ... been forced to fold, consolidate, or carry on without ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide ... kill nematodes. Nematodes are microscopic parasitic roundworms, found ... and inside other plants and animals. Nematicides have ... or other properties promoting migration through the soil. ... than 1,000 plant-parasitic nematodes. With more than 10,000 ...
Breaking Biology Technology:Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Biosciences, Inc. (Nasdaq: RDEA ) announced today that ... present at the following upcoming investor conferences: ... NY. Presentation: 1:40 p.m. EST on Tuesday, November 16, 2010; and ... New York, NY. Presentation: 1:00 p.m. EST on Tuesday, November ...
... appreciate the gravity-defying grace and exquisite balance of their feline ... the way cats lap milk? Researchers at MIT, Virginia ... cats lap and found that felines of all sizes take ... The results will be published in the November 11 online ...
... is available in German . ... microelectronic components gradually being replaced by nanoelectronic ones. ... present stage the most commonly used material in ... miniaturization and technological progress. New electronic materials are ...
Cached Biology Technology:Ardea Biosciences to Present at Two Upcoming Investor Conferences 2Ardea Biosciences to Present at Two Upcoming Investor Conferences 3Cats show perfect balance even in their lapping 2Cats show perfect balance even in their lapping 3Cats show perfect balance even in their lapping 4Step by step toward tomorrow's nanomaterial 2
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... system cells can be genetically modified to brandish a ... kill leukemic cells. This finding, from researchers at St. ... the outcome of children who receive treatment for acute ... of the St. Jude study are published in the ...
... St. Jude Children's Research,Hospital have discovered that the ... bacteria helps these germs invade the human bloodstream. ... Journal, could help,scientists develop a vaccine that is ... The St. Jude researchers,determined the shape of a ...
... in on cancer cells spreading throughout the body, while ... whole new weapon in the fight against tough-to-treat metastatic ... researchers. , The compounds, called synthetic migrastatin analogues, prevented ... in mice, and are the first to target only ...
Cached Biology News:Genetically modified natural killer immune cells attack, kill leukemia cells 2New comparative toxicogenomics database 2New comparative toxicogenomics database 3First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 2First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers 3
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... acid synthetic peptide whose sequences are derived from mouse resistin protein. ... S(21) - S - M - P - L - C ... I - D - K - K - I - K ... be used for neutralization and control experiments with the polyclonal antibody ...
... peptidomimetics built on the flexible and ... These microarrays are available as part ... Service. Custom Probe Content ... specified. Thousands of customer specified peptide ...
... These extended-length microarrays are custom designed to ... configurations are available: 8,455 features per array ... 22,575 features per array (1 array/slide). ... probe length - This extended length ...
Biology Products: